Research Article

O-GlcNAcylation Is Essential for Autophagy in Cardiomyocytes

Houzhi Yu1,2, Li Wen3, and Yongxin Mu2

1Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
2Department of Medicine-Cardiology, University of California San Diego, 9500 Gilman Drive, Mail Code 0613-C, La Jolla California 92093-0613, USA
3Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Correspondence should be addressed to Yongxin Mu; yomu@ucsd.edu

Received 4 May 2020; Revised 21 June 2020; Accepted 27 July 2020; Published 11 August 2020

Academic Editor: Jon D. Lane

Copyright © 2020 Houzhi Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Since both O-GlcNAcylation and autophagy sense intracellular nutrient level, the alteration of those two pathways plays substantial roles in the progression of heart failure. Hence, determining the relationship between O-GlcNAcylation and autophagy is imperative to understand, prevent, and treat heart failure. However, the mechanism on how O-GlcNAcylation regulates autophagy in the heart is poorly investigated. In this study, we demonstrated that O-GlcNAcylation is required for autophagy in cardiomyocytes by utilizing an O-linked β-N-acetylglucosamine transferase (OGT) cardiomyocyte-specific knockout mouse model for the first time. We also identified that OGT might regulate the initiation of autophagy in cardiomyocytes through promoting the activity of ULK1 by O-GlcNAcylation. In conclusion, our findings provide new insights into the molecular mechanisms underlying heart dysfunction and benefit the development of treatments for heart failure.

1. Introduction

O-GlcNAcylation is an important posttranslation modification of proteins by the addition of O-linked β-N-acetylglucosamine (O-GlcNAc) moieties at serine or threonine residues. Similar to protein phosphorylation, which also occurs on serine or threonine residues, O-GlcNAcylation is dynamic. In contrast to phosphorylation, which is catalyzed and removed by hundreds of kinases and phosphatases with relative substrate specificities, O-GlcNAcylation is catalyzed and removed by a single pair of enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively [1, 2]. Increased O-GlcNAcylation in a hypertrophic or failing heart has been reported from human patients and animal models [3, 4]. Additionally, previous studies using both in vitro and in vivo models have suggested that increased O-GlcNAcylation plays a cardioprotective role in acute cardiac dysfunctions, yet it may have deleterious effects on cardiac function in chronic conditions [3]. Genetic knockout of OGT at embryonic stage in mice led to congenital heart diseases, resulting in partial postnatal lethality [5] and cardiac hypertrophy among surviving mice [6]. The acute loss of OGT in cardiomyocytes also exacerbated heart failure induced by myocardium ischemia [7].

Autophagy is a conserved mechanism for the degradation of intracellular elements and plays an essential role in protein homeostasis and the quality control of subcellular organelles [8–12]. Although sometimes autophagy can induce cell death with unique morphological changes, in most cases, autophagy plays protective or adaptive roles and prevents cell death [12, 13]. Autophagy is essential in maintaining cardiac structure and function at both baseline by degrading misfolded proteins and damaged organelles and during stress by limiting the cardiac damage in different pathological conditions such as ischemia, starvation, and hemodynamic overload [14, 15]. A decreased level of autophagy was proven to contribute to the progression of heart failure and aging [16, 17]. Hence, autophagy plays an important role in mediating cardiac homeostasis and adaption to aging, stress, and myocardial injury.

Recently, the relationship between O-GlcNAcylation and autophagy is gaining more interests, and studies have shown that O-GlcNAcylation indeed regulates autophagy [18, 19]. Some reports have shown that O-GlcNAcylation negatively
regulates autophagy in the heart. Noteworthy, those studies have used Streptozotocin (STZ) to increase O-GlcNAcylation in vivo [20, 21] by damaging pancreatic β cells [22]. However, damaged β cells and STZ’s well-known side effects on other organs [22] may compromise the relationship between O-GlcNAcylation and autophagy specifically in the heart or cardiomyocytes.

Here, we used the Cre-Loxp system to specifically knock out OGT and abolish O-GlcNAcylation in cardiomyocytes. We found that the loss of O-GlcNAcylation in cardiomyocytes attenuated autophagy, especially under fasting condition. Also, data from isolated neonatal cardiomyocytes showed that the loss of OGT affected the early stage of autophagy. Moreover, we identified that Unc-51-Like Autophagy Activating Kinase 1 (ULK1), an essential kinase for initiating autophagy flux, was O-GlcNAcylated in cardiomyocytes, and the level of O-GlcNAcylation of ULK1 was diminished in OGT knockout cardiomyocytes. Taken together, our data demonstrated that O-GlcNAcylation is essential for the initiation of autophagy in cardiomyocytes. Our findings provide novel insights on the regulation of autophagy in heart diseases.

2. Materials and Methods

2.1. Animal Models. Ogtlox/loxflo(f/f) mice was purchased from Jackson Lab (Stock No: 004860 | OGTf). Floxed female mice were crossed with α-Mhc-MerCreMer transgenic mice [23] to create Ogtfl/f; α-Mhc-MerCreMer-inducible KO (iKO) mice. All mice were of a mixed 129/SvJ and C57BL/6 background. Genotypes of the mice were confirmed by polymerase chain reaction (PCR) analysis using tail genomic DNA and Ogt primers (forward: 5′-CATCTC TCCAGCCCCCAAAACTG-3′, reverse: 5′-GACGGAAGCA GGAGGGGGAGGAC-3′) and Cre primers (forward: 5′- GTTCCAGAAACCTGTAGGACA-3′; reverse: 5′-CTAG AGCCCTGTTTTGCACTTGTC-3′). All animal procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego, with an approved protocol# S01049.

2.2. Tamoxifen Induction. 4-Hydroxytamoxifen was dissolved in sesame oil at a concentration of 10 mg/mL. Adult (2-month-old) Ogtfl/fl and Ogtlox/lox mice were treated with 4-hydroxytamoxifen by intraperitoneal injection once daily for 5 days with a dosage of 30 mg/kg body weight. Ten days after the last dose of tamoxifen, mice were either given unlimited food or fasted for 12 hours, followed by heart collection for western blot analysis.

2.3. Adenoviral Vectors, Reagents, and Antibodies. Adenoviruses expressing Cre and lacZ (Ad-Cre and Ad-lacZ) were obtained from the UCSD Viral Vector Core. Adenovirus expressing mRFP-GFP-LC3 (Ad-tf-LC3) was provided as a gift from Dr. Junichi Sadoshima. 4-Hydroxytamoxifen (H7904), Thiamet-G (TMG, SML0244), and Bafilomycin A1 (SML1661) were purchased from Sigma-Aldrich. Antibodies used in this study included RL2 (MA1-072, Thermo Fisher Scientific), OGT (61355, Active Motif), ULK1 (4773, Cell Signaling), pATG16L1 (ab195242, Abcam), LC3B (2775, Cell Signaling), SQSTM1 (GP61-C, Progen), ubiquitin (sc8017, Santa Cruz), and GAPDH (sc365062, Santa Cruz).

2.4. Protein Isolation and Western Blot Analysis. Total protein extracts were prepared by suspending ground heart tissue or isolated cardiomyocytes in a urea lysis buffer (8 M urea, 2 M thiourea, 3% SDS, 75 mM DTT, 0.03% bromophenol blue, 0.05 M Tris-HCl, pH 6.8). Protein lysates were separated on 4% to 12% SDS-PAGE gels (Thermo Fisher Scientific) and transferred at 4°C overnight onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour in TBS containing 0.1% Tween-20 (TBST) and 5% dry milk, the membranes were incubated at 4°C overnight with the indicated primary antibodies in a blocking buffer. Blots were washed and incubated with the appropriate HRP-conjugated secondary antibodies (1:5000) for 1 hour at room temperature. Immunoreactive protein bands were visualized using an ECL reagent (Thermo Fisher Scientific).

2.5. Immunoprecipitation. After the transduction with Ad-LacZ or Ad-Cre viruses for 48 hours, neonatal cardiomyocytes were lysed in a RIPA lysis buffer (50 mM Tris, 10 mM EDTA, 150 mM NaCl, 0.25% deoxycholic acid, 0.1% SDS, 2% NP-40 substitute, and 0.01% sodium azide). Cell lysates were rotated in the RIPA buffer with 10 μL of RL2 or ULK1 antibody at 4°C overnight. Normal IgG (Santa Cruz) was used as a negative control. Next, 25 μL of PBS-washed protein G beads (Thermo Scientific) were resuspended and incubated in the lysate-antibody complexes for 2 hours at 4°C. After washing 3 times with the RIPA lysis buffer, beads were incubated in 4 × LDS buffer (BioRad) at 70°C for 10 minutes, and the supernatants were collected. The immunoprecipitates and input lysate were gel electrophoresed and immunoblotted with the antibodies against O-GlcNAc (RL2) and ULK1.

2.6. Neonatal Mouse Cardiomyocyte Isolation and Treatments. Neonatal mouse cardiomyocytes were prepared as previously described [24] and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% horse serum, 5% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin for 24 hours before adenovirus transduction or other treatments. After being transduced with adenoviruses at MOI of 50, cardiomyocytes were cultured for additional 36 or 48 hours. Wild-type neonatal cardiomyocytes were treated with TMG (25 μM) for 48 hours before other treatments. Right before collection, cardiomyocytes were treated with Bafilomycin A1 (100 nM) for 4 hours or subjected to starvation with serum-free medium for 18 hours.

2.7. Fluorescent Microscopy. 48 hours after the transduction with Ad-tf-LC3 along with Ad-LacZ or Ad-Cre, cardiomyocytes were fixed with 4% paraformaldehyde for 5 min before confocal imaging. For immunostaining of pATG16L1, Ad-LacZ or Ad-Cre, transduced neonatal cardiomyocytes were fixed with 4% paraformaldehyde for 5 min and blocked in the blocking buffer (PBS with 1% BSA, 5% donkey serum,
and 0.2% Triton 100) for 2 hours. They were then incubated with pATG16L1 antibody (1:200 in blocking buffer) overnight followed by a secondary antibody (1:300 in blocking buffer) incubation for 2 hours and confocal imaging.

2.8. Statistics. Data were presented as the mean ± SEM unless indicated otherwise. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software), with a 2-tailed Student’s t test. P values of less than 0.05 were considered statistically significant.

3. Results

3.1. Deletion of Cardiomyocyte OGT Leads to the Attenuation of Autophagy in the Mouse Heart. To explore the possible effects of O-GlcNAcylation on autophagy in the heart, we crossed Og$^{f/f}$ females with inducible α-MHC-MerCreMer male mice to generate Og$^{f/f}$; α-MHC-MerCreMer mice, which were injected with tamoxifen for 5 days to generate OGT cardiac knockouts (hereafter icKO). Meanwhile, age-matched Og$^{f/f}$ mice injected with the same doses of tamoxifen were used as controls. Ten days after the last dose of tamoxifen, when the icKO mice did not show heart dysfunction [6], western blot with RL2 and OGT antibodies showed that global O-GlcNAcylation and OGT dramatically decreased in icKO hearts. Under fed condition, the LC3-II level in the heart was not statistically different between control and icKO mice, although LC3-II in icKO mice was decreased (Figure 1). In contrast, the SQSTM1 level in icKO mice increased slightly but significantly (Figure 1). The most potent known physiological inducer of autophagy is starvation, and fasting has been widely used to investigate autophagy in mouse models [25]. Thus, we next investigated whether O-GlcNAcylation affected cardiac autophagy when mice were subjected to fasting. Surprisingly, the LC3-II level was significantly decreased in icKO mice when they were subjected to fasting. The SQSTM1 level in icKO mouse heart was further elevated accordingly (Figure 1). These data suggested that O-GlcNAcylation in cardiomyocytes is indispensable for autophagy under fasting condition, while it has only a mild influence on autophagy at the basal level.

3.2. Deletion of OGT in Isolated Neonatal Cardiomyocytes Attenuates Autophagy. To investigate whether OGT regulated autophagy in cardiomyocytes in a cell autonomous manner, we isolated neonatal cardiomyocytes from newborn pups from Og$^{f/f}$ female and Og$^{f/f}$ crossings. Those isolated neonatal cardiomyocytes were transduced with adenovirus expressing Cre recombinase (Ad-Cre) to delete OGT. Cells transduced with adenovirus expressing LacZ (Ad-LacZ) were used as control. Western blot showed that the levels of O-GlcNAcylation and OGT were dramatically decreased in Ad-Cre-treated cells (Figure 2(a)). LC3-II was significantly downregulated in knockout cells, regardless whether the cells were cultured in complete medium (nutrient) or subjected to starvation (starved) as described in Materials and Methods. Also consistent with the previous in vivo result (Figure 1), SQSTM1 was increased in knockout cells under both nutrient and starved conditions (Figure 2(a)). To further confirm
the attenuation of autophagy in OGT knockout cardiomyocytes, the cardiomyocytes were transduced with adenovirus expressing tandem fluorescent mRFP-GFP-LC3 (Ad-tf-LC3). Ad-tf-LC3 allows the detailed monitoring of autophagy flux, because LC3 puncta labeled with GFP and mRFP represent autophagosomes, whereas those labeled with mRFP alone represent autolysosomes [26]. Indeed, under nutrient condition, the numbers of both mRFP-labeled autolysosomes and yellow autophagosomes were decreased in OGT knockout cardiomyocytes (Figure 2(b)). Collectively, our data suggested that O-GlcNAcylation is required for autophagy in mouse cardiomyocytes.

3.3. OGT Regulates the Early Stages of Autophagy in Cardiomyocytes. To further investigate how OGT regulates autophagy in cardiomyocytes, we treated the control and OGT deleted neonatal cardiomyocytes with or without Bafilomycin A (BafA), a commonly used inhibitor of autophagy through preventing autophagosome-lysosome fusion and acidification of lysosome [27]. Clearly, western blot showed that BafA treatment induced an accumulation of LC3-II in control cardiomyocytes but to a much lower extent in OGT deleted cardiomyocytes (Figure 3(a)). Those data indicated that the loss of OGT in cardiomyocytes attenuated the early stages of autophagy flux. A recent report has shown that
Figure 3: OGT regulates the early stage of autophagy in cardiomyocytes. (a) Left panel, western blot analysis for autophagy of untreated or Bafilomycin A-treated Ad-LacZ or Ad-Cre-infected Ogt<sup>fl/fl</sup> neonatal cardiomyocytes, using antibody against O-GlcNAc, OGT, and LC3. GAPDH was detected as loading control. Right panel, quantification of western blot results in left panel, n = 3 for each group. *Significantly different; M.W.: molecular weight. (b) Left panel, western blot analysis for autophagy of Ad-LacZ- or Ad-Cre-infected Ogt<sup>fl/fl</sup> and/or Ogt<sup>fl/y</sup> neonatal cardiomyocytes with either full medium (nutrient) or starving medium (starved), using antibody against pATG16L. GAPDH was detected as a loading control. Right panel, quantification of western blot results in the left panel, n = 4 for each group. *Significantly different; M.W.: molecular weight. (c) Left panel, representative immunomicroscopic images of pATG16L puncta (green) in Ad-LacZ- and Ad-Cre-infected Ogt<sup>fl/fl</sup> and/or Ogt<sup>fl/y</sup> neonatal cardiomyocytes, costained with alpha-actinin (gray) and DAPI (blue). Right panel, quantification of pATG16L-positive puncta per cell, n = 50 cells each group. *Significantly different.
the level of phosphorylated ATG16L1 (pATG16L1) correlates with the amount of newly formed autophagosome, and it has suggested that the pATG16L1 level could determine the rate of autophagy [28]. Hence, we took advantage of the newly generated antibody that recognizes pATG16L1 to confirm our finding. Consistently, western blot showed that the level of pATG16L1 was decreased in OGT deleted cardiomyocytes, under both nutrient and starved conditions (Figure 3(b)). Immunostaining also showed that the number of pATG16L1-positive puncta in OGT knockout neonatal cardiomyocytes under nutrient condition was decreased (Figure 3(c)). These data suggested that the loss of OGT in cardiomyocytes most likely affects autophagy induction rather than the late stages of autophagy.

3.4. Elevated O-GlcNAcylation in Neonatal Mouse Cardiomyocytes Promotes Autophagy. To check whether elevated O-GlcNAcylation in cardiomyocytes has the opposite effect on autophagy, we treated wild-type neonatal mouse cardiomyocytes with 25 μmol/L TMG, an OGA-specific inhibitor. Western blot showed that TMG treatment indeed significantly increased the level of O-GlcNAcylation in cardiomyocytes (Figure 4(a)). Consequently, the LC3-II level in cardiomyocytes was also increased significantly by TMG treatment, both at the basal level and with BafA (Figure 4(a)). Also, the pATG16L1 level was increased in cardiomyocytes treated with TMG (Figure 4(b)). Collectively, these data indicated that elevated O-GlcNAcylation in cardiomyocytes promotes autophagy.

3.5. ULK1 Is O-GlcNAcylated in Cardiomyocytes. ULK1 is a key factor in controlling the initiation of autophagy [12]. Both in vivo and in vitro data strongly suggested that ULK1 is required for autophagy in cardiomyocytes [29].

Figure 4: Enhanced O-GlcNAcylation stimulates autophagy in cardiomyocytes. (a) Left panel, western blot analysis for autophagy of wild-type neonatal cardiomyocytes with different treatments as indicated, using antibody against O-GlcNAc and LC3. GAPDH was detected as a loading control. Right panel, quantification of western blot results in the left panel, n = 3 for each group. *Significantly different; M.W.: molecular weight. (b) Left panel, western blot analysis of control or TMG-treated wild-type neonatal cardiomyocytes, using antibodies against O-GlcNAc and pATG16L. GAPDH was detected as a loading control. Right panel, quantification of western blot results in the left panel, n = 3 for each group. *Significantly different; M.W.: molecular weight.
In addition, ULK1 is also responsible for the phosphorylation of ATG16L1 [28]. Hence, we checked whether ULK1 was decreased in OGT deleted cardiomyocytes. Surprisingly, ULK1 showed an even higher protein level in OGT knockout cardiomyocytes (Figure 5(a)), excluding the contribution of decreased ULK1 to OGT deletion-induced autophagy attenuation. A recent report has shown that O-GlcNAcylation of ULK1 is required for ULK1-mediated autophagy in liver cells [19], which prompted us to examine whether ULK1 was O-GlcNAcylated in cardiomyocytes. Immunoprecipitation showed that ULK-1 was O-GlcNAcylated in cardiomyocytes. And the level of ULK1 O-GlcNAcylation was dramatically decreased in OGT knockout cardiomyocytes (Figures 5(b) and 5(c)). These data suggested that OGT control the initiation of autophagy in cardiomyocytes through the regulation of ULK1 O-GlcNAcylation.

4. Discussion

Previous studies have showed that cardiomyocyte OGT or O-GlcNAcylation was essential for cardiac function at both the basal level and under stress such as ischemia [6, 7], and the loss of OGT promoted cardiomyocyte’s apoptosis [6, 7]. Interestingly, upregulation of autophagy during heart ischemia and reperfusion has also been shown to be cardiac-protective and prevented apoptosis of cardiomyocytes [30–32]. Therefore, we anticipated that the protective effect of O-GlcNAcylation in cardiomyocytes is mediated,
at least partially, via the promoting of autophagy especially under stress. Indeed, our data from both in vivo and in vitro models clearly demonstrated that the loss of OGT in cardiomyocytes attenuated autophagy

Interestingly, we found that the loss of O-GlcNAcylation in the heart decreased autophagy only when mice were subjected to starvation, while the loss of O-GlcNAcylation in isolated neonatal cardiomyocytes attenuated autophagy under both nutrient and starved conditions. One possible explanation is that during the process of isolation, the isolated cardiomyocytes might have already gone through stress, which increased the basic requirement of autophagy. Another explanation is that underdeveloped neonatal cardiomyocytes and mature adult cardiomyocytes might behave differently in the extent of autophagy regulations.

Of note, our results were different from the previous studies which showed that elevated O-GlcNAcylation blunted autophagy in the heart and cardiomyocytes [20, 21]. In those studies, STZ was used to elevate O-GlcNAcylation because STZ can induce hyperglycemia by damaging β cells. Consequently, STZ induces altered O-GlcNAcylation globally instead of just in cardiomyocytes, preventing the effects of O-GlcNAcylation in cardiomyocytes on autophagy to be elucidated. Also, STZ treatment in animals has numerous side effects [22], which further compromise the relationship between O-GlcNAcylation and autophagy inside cardiomyocytes. Our results from the OGT cardiomyocyte-specific knockout mouse model demonstrated that O-GlcNAcylation promotes autophagy in cardiomyocyte cell autonomously.

We also showed that O-GlcNAcylation is required for the early stages of autophagy because LC3-II level was decreased even with BafA treatment. Additionally, pATG16L1 level, a novel marker of newly formed autophagosome [28], was also decreased when OGT was knocked out in cardiomyocytes. Consistently, ULK1, a key regulator of autophagy at the early stage, was shown to be O-GlcNAcylated in cardiomyocytes, and O-GlcNAcylation of ULK1 was diminished when OGT was knocked out. In line with our findings, ULK1 cardiomyocyte-specific knockout mice show autophagy defects under stress [29]. Considering that ULK1 is a critical regulator of autophagy initiation and its O-GlcNAcylation is required for the induction of autophagy in other cell types [19, 33], we anticipate that OGT promotes autophagy through regulating ULK1 activity by O-GlcNAcylation in cardiomyocytes. Future studies are needed for confirmation.

In conclusion, using a cardiomyocyte-specific genetic deletion mouse model, for the first time, we demonstrated that O-GlcNAcylation is required for autophagy in cardiomyocytes especially under stress conditions. We also found that O-GlcNAcylation promotes initiation of autophagy probably through the regulation of ULK1 activity in cardiomyocytes. Our findings provide a better understanding of heart dysfunction and should be considered for their potentials in the prevention and treatment of heart failure.

**Data Availability**

All data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] M. R. Bond and J. A. Hanover, “A little sugar goes a long way: the cell biology of O-GlcNAc,” *The Journal of Cell Biology*, vol. 208, no. 7, pp. 869–880, 2015.

[2] C. R. Torres and G. W. Hart, “Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc,” *The Journal of Biological Chemistry*, vol. 259, no. 5, pp. 3308–3317, 1984.

[3] F. Mailleux, R. Gelinas, C. Beauloye, S. Horman, and L. Bertrand, “O-GlcNAcylation, enemy or ally during cardiac hypertrophy development,” *Biochimica et Biophysica Acta*, vol. 1862, no. 12, pp. 2232–2243, 2016.

[4] H. Yki-Järvinen, C. Vogt, P. Iozzo et al., “UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues,” *Diabetologia*, vol. 40, no. 1, pp. 76–81, 1997.

[5] Y. Mu, H. Yu, T. Wu, J. Zhang, S. M. Evans, and J. Chen, “O-linked β-N-acetylglucosamine transferase plays an essential role in heart development through regulating angiopoietin-1,” *PLoS Genetics*, vol. 16, no. 4, article e1008730, 2020.

[6] L. J. Watson, H. T. Facundo, G. A. Ngoh et al., “O-linked β-N-acetylglucosamine transferase is indispensable in the failing heart,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 41, pp. 17797–17802, 2010.

[7] L. J. Watson, B. W. Long, A. M. DeMartino et al., “Cardiomyocyte Ogt is essential for postnatal viability,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 306, no. 1, pp. H142–H153, 2014.

[8] A. M. Choi, S. W. Ryter, and B. Levine, “Autophagy in human health and disease,” *The New England Journal of Medicine*, vol. 368, no. 7, pp. 651–662, 2013.

[9] G. Kroemer, “Autophagy: a druggable process that is deregulated in aging and human disease,” *The Journal of Clinical Investigation*, vol. 125, no. 1, pp. 1–4, 2015.

[10] Y. Maejima, “The critical role of autophagy in heart failure,” *Nihon Yakurigaku Zasshi*, vol. 151, no. 3, pp. 100–105, 2018.

[11] N. Mizushima and M. Komatsu, “Autophagy: renovation of cells and tissues,” *Cell*, vol. 147, no. 4, pp. 728–741, 2011.

[12] S. Scarretta, Y. Maejima, D. Zabllocki, and J. Sadoshima, “The role of autophagy in the heart,” *Annual Review of Physiology*, vol. 80, no. 1, pp. 1–26, 2018.

[13] Y. Liu, S. Shoji-Kawata, R. M. Sumpter et al., “Autosis is a Na⁺:K⁺-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 51, pp. 20364–20371, 2013.

[14] Y. Ikeda, A. Shirakabe, Y. Maejima et al., “Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress,” *Circulation Research*, vol. 116, no. 2, pp. 264–278, 2015.

[15] A. Nakai, O. Yamaguchi, T. Takeda et al., “The role of autophagy in cardiomyocytes in the basal state and in response to
hemodynamic stress,” *Nature Medicine*, vol. 13, no. 5, pp. 619–624, 2007.

[16] T. Eisenberg, M. Abdellatif, S. Schroeder et al., “Cardioprotection and lifespan extension by the natural polynucleoside spermidine,” *Nature Medicine*, vol. 22, no. 12, pp. 1428–1438, 2016.

[17] A. Shirakabe, Y. Ikeda, S. Sciarretta et al., “Aging and autophagy in the heart,” *Circulation Research*, vol. 118, no. 10, pp. 1563–1576, 2016.

[18] B. Guo, Q. Liang, L. Li et al., “O-GlcNAc-modification of SNAP-29 regulates autophagosome maturation,” *Nature Cell Biology*, vol. 16, no. 12, pp. 1215–1226, 2014.

[19] H. B. Ruan, Y. Ma, S. Torres et al., “Calcium-dependent O-GlcNAc signaling drives liver autophagy in adaptation to starvation,” *Genes & Development*, vol. 31, no. 16, pp. 1655–1665, 2017.

[20] L. Huang, P. Yuan, P. Yu et al., “O-GlcNAc-modified SNAP29 inhibits autophagy-mediated degradation via the disturbed SNAP29-STX17-VAMP8 complex and exacerbates myocardial injury in type 1 diabetic rats,” *International Journal of Molecular Medicine*, vol. 42, no. 6, pp. 3278–3290, 2018.

[21] S. A. Marsh, P. C. Powell, L. J. Dell’Italia, and J. C. Chatham, “Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart,” *Life Sciences*, vol. 92, no. 11, pp. 648–656, 2013.

[22] M. L. Graham, J. L. Janecek, J. A. Kittredge, B. J. Hering, and H. J. Schuurman, “The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources,” *Comparative Medicine*, vol. 61, no. 4, pp. 356–360, 2011.

[23] D. S. Sohal, M. Nghiem, M. A. Crackower et al., “Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein,” *Circulation Research*, vol. 89, no. 1, pp. 20–25, 2001.

[24] X. Fang, J. Bogomolovas, T. Wu et al., “Loss-of-function mutations in co-chaperone BAG3 destabilize small HSPs and cause cardiomyopathy,” *The Journal of Clinical Investigation*, vol. 127, no. 8, pp. 3189–3200, 2017.

[25] M. Moulis and C. Vindis, “Methods for measuring autophagy in mice,” *Cell*, vol. 6, no. 2, 2017.

[26] N. Harirhan, P. Zhai, and J. Sadoshima, “Oxidative stress stimulates autophagic flux during ischemia/reperfusion,” *Antioxidants & Redox Signaling*, vol. 14, no. 11, pp. 2179–2190, 2011.

[27] C. Mauvezin and T. P. Neufeld, “Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagolysosome fusion,” *Autophagy*, vol. 11, no. 8, pp. 1437–1438, 2015.

[28] W. Tian, R. Alsaadi, Z. Guo et al., “An antibody for analysis of autophagy induction,” *Nature Methods*, vol. 17, no. 2, pp. 232–239, 2020.

[29] T. Saito, J. Nah, S. I. Oka et al., “An alternative mitophagy pathway mediated by Rab9 protects the heart against ischemia,” *The Journal of Clinical Investigation*, vol. 129, no. 2, pp. 802–819, 2019.

[30] L. Yan, D. E. Vatner, S. J. Kim et al., “Autophagy in chronically ischemic myocardium,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 39, pp. 13807–13812, 2005.

[31] A. Hamacher-Brady, N. R. Brady, and R. A. Gottlieb, “Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes,” *Journal of Biological Chemistry*, vol. 281, no. 40, pp. 29776–29787, 2006.

[32] S. Sciarretta, P. Zhai, D. Shao et al., “Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome,” *Circulation*, vol. 125, no. 9, pp. 1134–1146, 2012.

[33] K. E. Pyo, C. R. Kim, M. Lee, J. S. Kim, K. I. Kim, and S. H. Baek, “ULK1 O-GlcNAcylation is crucial for activating VPS34 via ATG14L during autophagy initiation,” *Cell Reports*, vol. 25, no. 10, pp. 2878–2890.e4, 2018, e2874.